| Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration‐resistant prostate cancer ES Antonarakis, EI Heath, DC Smith, D Rathkopf, AL Blackford, DC Danila, ... The oncologist 18 (2), 163-173, 2013 | 210 | 2013 |
| Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor SK Kachhap, N Rosmus, SJ Collis, MSQ Kortenhorst, MD Wissing, ... PloS one 5 (6), e11208, 2010 | 186 | 2010 |
| Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer J Mendonca, A Sharma, HS Kim, H Hammers, A Meeker, A De Marzo, ... Oncotarget 5 (15), 6102, 2014 | 69 | 2014 |
| Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy. QDZ Geng H, Xue C, Mendonca J, Sun XX, Liu Q, Reardon PN, Chen Y, Qian K ... Nature Communications, 2018 | 57 | 2018 |
| The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion A Sharma, J Mendonca, J Ying, HS Kim, JE Verdone, JC Zarif, M Carducci, ... Molecular oncology 11 (6), 655-669, 2017 | 45 | 2017 |
| Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors MD Wissing, J Mendonca, MSQ Kortenhorst, NS Kaelber, M Gonzalez, ... The FASEB Journal 27 (10), 4279, 2013 | 44 | 2013 |
| Supraphysiologic testosterone induces ferroptosis and activates immune pathways through nucleophagy in prostate cancer R Kumar, J Mendonca, O Owoyemi, K Boyapati, N Thomas, ... Cancer research 81 (23), 5948-5962, 2021 | 35 | 2021 |
| C/EBPβ regulates sensitivity to bortezomib in prostate cancer cells by inducing REDD1 and autophagosome–lysosome fusion DJ Barakat, J Mendonca, T Barberi, J Zhang, SK Kachhap, I Paz-Priel, ... Cancer letters 375 (1), 152-161, 2016 | 35 | 2016 |
| Combining the pan‐aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer CJ Paller, MD Wissing, J Mendonca, A Sharma, E Kim, HS Kim, ... Cancer medicine 3 (5), 1322-1335, 2014 | 35 | 2014 |
| Disruption of basal lamina components in neuromotor synapses of children with spastic quadriplegic cerebral palsy KG Robinson, JL Mendonca, JL Militar, MC Theroux, KW Dabney, ... PLoS One 8 (8), e70288, 2013 | 35 | 2013 |
| NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability S Croessmann, HY Wong, DJ Zabransky, D Chu, J Mendonca, A Sharma, ... Proceedings of the National Academy of Sciences 112 (37), 11583-11588, 2015 | 33 | 2015 |
| Identification of cetrimonium bromide and irinotecan as compounds with synthetic lethality against NDRG1 deficient prostate cancer cells MD Wissing, J Mendonca, E Kim, E Kim, JS Shim, NS Kaelber, H Kant, ... Cancer Biology & Therapy 14 (5), 401-410, 2013 | 17 | 2013 |
| Identification of neuromuscular junctions by correlative confocal and transmission electron microscopy S Modla, J Mendonca, KJ Czymmek, RE Akins Journal of neuroscience methods 191 (2), 158-165, 2010 | 15 | 2010 |
| Muscadine grape skin extract inhibits prostate cancer cells by inducing cell-cycle arrest, and decreasing migration through heat shock protein 40 DN Ignacio, KD Mason, EC Hackett-Morton, C Albanese, L Ringer, ... Heliyon 5 (1), 2019 | 12 | 2019 |
| Supraphysiological testosterone induces ferroptosis and activates NF-kappaB mediated immune pathways in prostate cancer through nucleophagy J Mendonca, R Kumar, O Owoyemi, K Boyapati, N Thomas, ... bioRxiv, 2020.09. 10.286252, 2020 | 2 | 2020 |
| Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy (vol 9, 4972, 2018) H Geng, C Xue, J Mendonca, XX Sun, Q Liu, PN Reardon, Y Chen, ... Nature Communications 10, 2019 | 2 | 2019 |
| Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity J Mendonca, A Sharma, S Kachhap Asian Journal of Andrology 17 (3), 435-436, 2015 | 2 | 2015 |
| CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptor. R Kumar, J Mendonca, A Shetty, Y Yang, O Owoyemi, LC Wilson, ... bioRxiv, 2024.02. 13.579966, 2024 | 1 | 2024 |
| Supraphysiological androgens activate innate immune signaling in prostate cancer J Mendonca, O Owoyemi, M Rosen, M Carducci, M Markowski, ... Cancer Research 79 (13_Supplement), 517-517, 2019 | 1 | 2019 |
| Abstract B067: CRM1 inhibitor selinexor induces DNA damage repair-related vulnerability in prostate cancer cells R Kumar, J Mendonca, Y Yang, A Shetty, L Wilson, K Boyapati, ... Cancer Research 83 (11_Supplement), B067-B067, 2023 | | 2023 |
